pCMV-HA-JMJD2B Citations (4)

Originally described in: The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K Nature. 2006 Jul 20. 442(7100):307-11. PubMed Journal

---

Articles Citing pCMV-HA-JMJD2B

Articles
The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity. Levin M, Stark M, Assaraf YG. Oncotarget. 2018 Mar 30;9(24):16861-16882. doi: 10.18632/oncotarget.24717. eCollection 2018 Mar 30. PubMed
Increasing G9a automethylation sensitizes B acute lymphoblastic leukemia cells to glucocorticoid-induced death. Poulard C, Baulu E, Lee BH, Pufall MA, Stallcup MR. Cell Death Dis. 2018 Oct 10;9(10):1038. doi: 10.1038/s41419-018-1110-z. PubMed
Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks. Bayo J, Tran TA, Wang L, Pena-Llopis S, Das AK, Martinez ED. Cell Rep. 2018 Oct 23;25(4):1040-1050.e5. doi: 10.1016/j.celrep.2018.09.081. PubMed
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer. Wu MJ, Chen CJ, Lin TY, Liu YY, Tseng LL, Cheng ML, Chuu CP, Tsai HK, Kuo WL, Kung HJ, Wang WC. Theranostics. 2021 Jun 26;11(16):7779-7796. doi: 10.7150/thno.58729. eCollection 2021. PubMed

If you have published an article using this material, please email us at to have your article added to this page.